Acute Lymphoblastic Leukemia(T-ALL)-08
Yesheng from Fujian said, "If I had known about CAR-T at BIOOCUS Medical Group, I would have come earlier."
In September 2017, Yesheng developed facial rashes, which gradually spread and merged into patches. By February 28, 2018, bone marrow examination confirmed "acute T-cell lymphoblastic leukemia" after multiple courses of chemotherapy, with intermittent negative residual checks. All medications were stopped in June 2019.
In May 2021, Yesheng presented with masses in the oral-pharyngeal region and enlarged neck lymph nodes. Bone marrow re-examination confirmed a complete relapse of leukemia. On May 28, Yesheng was transferred to the Second Hematology Department for admission. After comprehensive examinations, the diagnosis was revised to "acute leukemia (T/myeloid biphenotypic)."
One cycle of chemotherapy did not induce remission in the bone marrow. On July 27, Yesheng received CD7 CAR-T cell infusion, followed by chemotherapy combined with autologous CD7 CAR-T cell therapy. Fifteen days after infusion, bone marrow examination showed negative residual disease, with a grade 1 cytokine release syndrome (CRS) reaction and no central nervous system adverse reactions.



description2
